Galapagos NV (GXE F) stock market data APIs
€24.5183
0(0%)
as of May 7, 2026
Try our APIs with
free plan!
Galapagos NV Financial Data Overview
Price chart is built with
Anychart
Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that is in phase 2 clinical trial in dermatomyositis and systemic lupus erythematosus; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc. The company was incorporated in 1999 and is headquartered in Mechelen, Belgium.
Prev. Close
24.5183
Open
24.5183
High
24.5183
Low
24.5183
52 wk Range
22.36-31.86
Market Cap
1 614 M
P/E Ratio
3.3063
Shares Outstanding
65 897 K
Revenue
1 112 M
Beta
0.115
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Galapagos NV data using free add-ons & libraries
Get Galapagos NV Fundamental Data
Galapagos NV Fundamental data includes:
- Net Revenue: 1 112 M
- EBITDA: 568 M
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-05-06
- EPS/Forecast: -0.51
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Galapagos NV News
New
Galapagos Reports First Quarter 2026 Financial Results and Provides Business Update
Galapagos NV Galapagos’ name change to Lakefront Biotherapeutics approved at the Company’s EGM (Euronext & NASDAQ: LKFT) Collaboration Agreement with Gilead to advance potential First and Be...
Galapagos’ Shareholders Adopt All Resolutions Proposed by the Board of Directors at the Annual and Extraordinary Shareholders’ Meetings 2026
Galapagos NV Mechelen, Belgium; April 28, 2026, 22:01 CET — Galapagos NV (Euronext & NASDAQ: GLPG) today announces that all resolutions proposed at the Company’s Annual and Extraordinary Sharehol...
RBC Cuts Galapagos NV (GLPG) Price Target to $28, Maintains Sector Perform Ahead of Q1
We recently compiled a list of the 9 Most Undervalued Healthcare Stocks to Buy Now. Galapagos NV is among the most undervalued stocks to invest in. TheFly reported on April 7 that RBC Capital Markets...
Galapagos NV (GLPG) Signs Agreement with Gilead on Ouro Medicines Assets
Galapagos NV (NASDAQ:GLPG) is one of the 7 Fastest Growing European Stocks to Invest In. On March 31, 2026, Galapagos NV (NASDAQ:GLPG) announced a binding agreement with Gilead Sciences (NASDAQ:GILD)...
Get Galapagos NV fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
